Novo Taps Veteran as CEO to Tackle Unprecedented Competition

Updated on
  • Joergensen joined Danish drugmaker as economist 25 years ago
  • Novo under pressure from rival drugs in its largest market

The man appointed to succeed Lars Rebien Soerensen as Novo Nordisk A/S’s chief executive officer says to expect continuity, but a challenging diabetes market may force him to diverge from Soerensen’s time-tested path.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.